- Home
- YMAB vs LYEL Comparison
YMAB vs LYEL Comparison
Compare YMAB & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAB
- LYEL
- Stock Information
- Founded
- YMAB 2015
- LYEL 2018
- Country
- YMAB United States
- LYEL United States
- Employees
- YMAB N/A
- LYEL N/A
- Industry
- YMAB Biotechnology: Pharmaceutical Preparations
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- YMAB Health Care
- LYEL Health Care
- Exchange
- YMAB Nasdaq
- LYEL Nasdaq
- Market Cap
- YMAB 218.4M
- LYEL 207.7M
- IPO Year
- YMAB 2018
- LYEL 2021
- Fundamental
- Price
- YMAB $3.89
- LYEL $0.40
- Analyst Decision
- YMAB Buy
- LYEL Sell
- Analyst Count
- YMAB 11
- LYEL 2
- Target Price
- YMAB $18.73
- LYEL $1.00
- AVG Volume (30 Days)
- YMAB 216.5K
- LYEL 648.7K
- Earning Date
- YMAB 05-13-2025
- LYEL 05-20-2025
- Dividend Yield
- YMAB N/A
- LYEL N/A
- EPS Growth
- YMAB N/A
- LYEL N/A
- EPS
- YMAB N/A
- LYEL N/A
- Revenue
- YMAB $87,685,000.00
- LYEL $61,000.00
- Revenue This Year
- YMAB N/A
- LYEL N/A
- Revenue Next Year
- YMAB $18.83
- LYEL N/A
- P/E Ratio
- YMAB N/A
- LYEL N/A
- Revenue Growth
- YMAB 3.38
- LYEL N/A
- 52 Week Low
- YMAB $3.84
- LYEL $0.39
- 52 Week High
- YMAB $17.47
- LYEL $2.88
- Technical
- Relative Strength Index (RSI)
- YMAB 40.44
- LYEL 37.66
- Support Level
- YMAB $3.76
- LYEL $0.41
- Resistance Level
- YMAB $4.60
- LYEL $0.51
- Average True Range (ATR)
- YMAB 0.33
- LYEL 0.05
- MACD
- YMAB -0.02
- LYEL 0.00
- Stochastic Oscillator
- YMAB 15.12
- LYEL 8.33
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.